Last reviewed · How we verify

Salvage antiretroviral therapy including raltegravir — Competitive Intelligence Brief

Salvage antiretroviral therapy including raltegravir (Salvage antiretroviral therapy including raltegravir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrase strand transfer inhibitor (INSTI). Area: Infectious Disease / Virology.

marketed Integrase strand transfer inhibitor (INSTI) HIV integrase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Salvage antiretroviral therapy including raltegravir (Salvage antiretroviral therapy including raltegravir) — Germans Trias i Pujol Hospital. Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Salvage antiretroviral therapy including raltegravir TARGET Salvage antiretroviral therapy including raltegravir Germans Trias i Pujol Hospital marketed Integrase strand transfer inhibitor (INSTI) HIV integrase
dolutegravir/abacavir/lamivudine dolutegravir/abacavir/lamivudine University College Dublin marketed Antiretroviral combination (INSTI + NRTIs) HIV integrase, HIV reverse transcriptase
Dolutegravir/Lamivudine Dolutegravir/Lamivudine Saint Michael's Medical Center marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase
Dolutegravir (DTG) Dolutegravir (DTG) ViiV Healthcare marketed Integrase strand transfer inhibitor (INSTI) HIV integrase
CAR CAR ViiV Healthcare marketed Antiretroviral combination therapy (INSTI + NNRTI) HIV integrase and HIV reverse transcriptase
Switch to DTG + 3TC Switch to DTG + 3TC Hospitales Universitarios Virgen del Rocío marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase
Bictegravir (BIC) Bictegravir (BIC) National Institute of Allergy and Infectious Diseases (NIAID) marketed Integrase strand transfer inhibitor (INSTI) HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrase strand transfer inhibitor (INSTI) class)

  1. ViiV Healthcare · 12 drugs in this class
  2. National Institute of Allergy and Infectious Diseases (NIAID) · 5 drugs in this class
  3. Merck Sharp & Dohme LLC · 5 drugs in this class
  4. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
  5. Germans Trias i Pujol Hospital · 1 drug in this class
  6. Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux · 1 drug in this class
  7. ANRS, Emerging Infectious Diseases · 1 drug in this class
  8. Massachusetts General Hospital · 1 drug in this class
  9. University of Colorado, Denver · 1 drug in this class
  10. MU-JHU CARE · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salvage antiretroviral therapy including raltegravir — Competitive Intelligence Brief. https://druglandscape.com/ci/salvage-antiretroviral-therapy-including-raltegravir. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: